Goldman Sachs Maintains Neutral on IDEAYA Biosciences, Raises Price Target to $35
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Neutral and raises the price target from $31 to $35.
Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Neutral and raises the price target from $31 to $35.